Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice
BACKGROUND: The FDA-approved small-molecule drug ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling. However, the potential regulation of neuroinflammatory...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145206/ https://www.ncbi.nlm.nih.gov/pubmed/30231870 http://dx.doi.org/10.1186/s12974-018-1308-0 |